A constructive research partnership with the
The 'Brain Imaging for Drug Discovery (BI2D)' research partnership with CERMEP was set up to develop and validate innovative neuroimaging tools for enhanced visualization of the impact of drugs on the brain, and more specifically on neurons and glial cells. The project is supported by a grant of nearly
The partnership has already led to two publications. The first, based on the use of a new functional ultrasound imaging technology, is a preclinical paper on THN201, entitled 'Pharmaco-fUS for characterizing drugs for Alzheimer's disease - The case of THN201, a drug combination of donepezil plus mefloquine,'[1] in Frontiers in Neuroscience. The article reports on research using mouse models that once again reveals how mefloquine potentiates the impact of donepezil on the activity of the brain structures involved in Alzheimer's disease, especially the hippocampus.
A second article entitled 'Functional ultrasound imaging to study brain dynamics: Application of pharmaco-fUS to atomoxetine'[2] has recently been published in Neuropharmacology. It reports on the use of ultrasound imaging as a tool to determine the profile of drugs targeting the central nervous system and improve understanding of the mechanism of action of drugs active in the brain.
Three other new scientific publications in prestigious neurology and pharmacology journals
The preclinical proof of concept of THN201,'Efficacy of THN201, a Combination of Donepezil and Mefloquine, to Reverse Neurocognitive Deficits in Alzheimer's Disease,'[3] was published in Frontiers in Neuroscience. This research revealed the superiority of THN201 over donepezil in terms of cognitive performance (learning and memory) for the first time in rodents, based on two models of Alzheimer's disease. It also highlights the role of connexins as therapeutic targets in Alzheimer's disease.
Another publication entitled 'Quantitative automated assays in living cells to screen for inhibitors of hemichannel function,' produced in collaboration with the CEA in Grenoble, is currently under publication in the scientific journal SLAS Discovery. It reports on the development of a screening tool for connexin hemichannel activity. More than 2,000 FDA- and EMA-approved drugs were screened and new compounds modulating connexin hemichannels were identified.
Finally, the article 'Innovative approaches in CNS drug discovery,' which describes innovative approaches to central nervous system disorders, is also set to be published soon in the journal Therapies. The article describes several innovative approaches in the field of drug discovery for CNS disorders and draws on research performed by
A presentation at the 33rd
Mathieu Charveriat,
'We are deeply honored that our research has been recognized by our peers, thereby demonstrating the scientific expertise of
ABOUT
The proprietary, adaptable
Contact:
Tel: 33 (0)6 07 76 82 83
(C) 2020 Electronic News Publishing, source